|View printer-friendly version|
|February 12, 2018 8:00 a.m.|
|Teva Announces U.S. Launch of QVAR® RediHaler™ (Beclomethasone Dipropionate HFA) Inhalation Aerosol|
First and Only Breath-Actuated Aerosol Inhaled Corticosteroid in
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180212005322/en/
QVAR® RediHaler™ product image (Photo: Business Wire)
“When it comes to the treatment of asthma, proper inhaler technique
remains a critical issue for patients. In fact, nearly 68 percent of
patients do not use their metered dose inhalers (MDIs) well enough to
benefit from the prescribed medication1, leading to
potentially uncontrolled asthma symptoms2,” said Dr.
QVAR® RediHaler™ differs from conventional metered-dose inhalers (MDIs) as it delivers medication via a breath-actuated inhaler, eliminating the need for hand-breath coordination during inhalation. QVAR® RediHaler™ administers the same active ingredient found in the previously available QVAR® (beclomethasone dipropionate HFA) Inhalation Aerosol, but utilizes innovative breath-actuated inhaler technology. QVAR® RediHaler™ was also designed to be ready for use, with no shaking or priming needed. Because the medication delivery is breath actuated, it should not be used with a spacer or volume holding chamber.
“QVAR® has been an available asthma treatment option for well over a decade, so we are excited by the new technology of QVAR® RediHaler™ that directly addresses an unmet need in the field of asthma management,” said Brendan O’Grady, Executive Vice President, North America Commercial at Teva. “By merging our breath-actuated inhaler technology with asthma medication, we hope to better serve the needs of the respiratory community and look forward to seeing the adoption of QVAR® RediHaler™ in the coming months.”
With the launch of QVAR® RediHaler™, Teva is discontinuing sales of the previously available QVAR®. Patients currently prescribed QVAR® and/or their caregivers are encouraged to speak with a healthcare professional about how this new treatment option may impact their treatment plan and how to obtain and use QVAR® RediHaler™, if desired. QVAR® RediHaler™ will be priced at parity to QVAR®.
QVAR® RediHaler™ (beclomethasone dipropionate HFA) Inhalation Aerosol is a breath-actuated inhaled prescription medicine used as a maintenance treatment for the prevention and control of asthma in people 4 years of age and older.
QVAR® RediHaler™ Inhalation Aerosol is not used to relieve sudden breathing problems and won’t replace a rescue inhaler.
Important Safety Information
Please see full Prescribing Information at http://www.qvarredihaler.com/Pdf/PI.pdf
A copy may be requested from the US Medical Information Contact
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the U.S. launch of QVAR® RediHaler™, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
1. Fink JB, Rubin BK. Problems with inhaler use: a call for improved
clinician and patient education. Respir Care. 2005;50(10):1360-1374.
Teva Pharmaceutical Industries Ltd.